Literature DB >> 2204813

The leucine zipper of c-Myc is required for full inhibition of erythroleukemia differentiation.

M J Smith1, D C Charron-Prochownik, E V Prochownik.   

Abstract

The leucine zipper motif has been observed in a number of proteins thought to function as eucaryotic transcription factors. Mutation of the leucine zipper interferes with protein dimerization and DNA binding. We examined the effect of point mutations in the leucine zipper of c-Myc on its ability to dimerize in vitro and to inhibit Friend murine erythroleukemia (F-MEL) differentiation. Glutaraldehyde cross-linking studies failed to provide evidence for homodimerization of in vitro-synthesized c-Myc protein, although it was readily demonstrated for c-Jun. Nevertheless, whereas transfected wild-type c-myc sequences strongly inhibited F-MEL differentiation, those with single or multiple mutations in the leucine zipper were only partially effective in this regard. Since the leucine zipper domain of c-Myc is essential for its cooperative effect in ras oncogene-mediated transformation, this study emphasizes the close relationship that exists between transformation and hematopoietic commitment and differentiation. c-Myc may produce its effects on F-MEL differentiation through leucine zipper-mediated heterodimeric associations rather than homodimeric ones.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2204813      PMCID: PMC361227          DOI: 10.1128/mcb.10.10.5333-5339.1990

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  41 in total

1.  Enhanced translation and increased turnover of c-myc proteins occur during differentiation of murine erythroleukemia cells.

Authors:  G D Spotts; S R Hann
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

2.  Functional role for c-myc in mitogenic response to platelet-derived growth factor.

Authors:  H A Armelin; M C Armelin; K Kelly; T Stewart; P Leder; B H Cochran; C D Stiles
Journal:  Nature       Date:  1984 Aug 23-29       Impact factor: 49.962

3.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

4.  Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.

Authors:  P J Southern; P Berg
Journal:  J Mol Appl Genet       Date:  1982

5.  Nuclear localization and DNA binding properties of a protein expressed by human c-myc oncogene.

Authors:  H Persson; P Leder
Journal:  Science       Date:  1984-08-17       Impact factor: 47.728

6.  Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes.

Authors:  H Land; L F Parada; R A Weinberg
Journal:  Nature       Date:  1983 Aug 18-24       Impact factor: 49.962

7.  Nucleotide sequence comparison of normal and translocated murine c-myc genes.

Authors:  L W Stanton; P D Fahrlander; P M Tesser; K B Marcu
Journal:  Nature       Date:  1984 Aug 2-8       Impact factor: 49.962

8.  V-myc- and c-myc-encoded proteins are associated with the nuclear matrix.

Authors:  R N Eisenman; C Y Tachibana; H D Abrams; S R Hann
Journal:  Mol Cell Biol       Date:  1985-01       Impact factor: 4.272

9.  Expression and characterization of the human c-myc DNA-binding protein.

Authors:  R A Watt; A R Shatzman; M Rosenberg
Journal:  Mol Cell Biol       Date:  1985-03       Impact factor: 4.272

10.  Fibroblast lines expressing activated c-myc oncogenes are tumorigenic in nude mice and syngeneic animals.

Authors:  E J Keath; P G Caimi; M D Cole
Journal:  Cell       Date:  1984-12       Impact factor: 41.582

View more
  18 in total

1.  A point mutation in the MyoD basic domain imparts c-Myc-like properties.

Authors:  M E Van Antwerp; D G Chen; C Chang; E V Prochownik
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

2.  Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3T3 cells.

Authors:  M D Sklar; E Thompson; M J Welsh; M Liebert; J Harney; H B Grossman; M Smith; E V Prochownik
Journal:  Mol Cell Biol       Date:  1991-07       Impact factor: 4.272

3.  Permanently blocked stem cells derived from breast cancer cell lines.

Authors:  Gangadharan B Sajithlal; Kristi Rothermund; Fang Zhang; David J Dabbs; Jean J Latimer; Stephen G Grant; Edward V Prochownik
Journal:  Stem Cells       Date:  2010-06       Impact factor: 6.277

4.  Chromatin redistribution of the DEK oncoprotein represses hTERT transcription in leukemias.

Authors:  Maroun Karam; Morgan Thenoz; Valérie Capraro; Jean-Philippe Robin; Christiane Pinatel; Agnès Lancon; Perrine Galia; David Sibon; Xavier Thomas; Sophie Ducastelle-Lepretre; Franck Nicolini; Mohamed El-Hamri; Youcef Chelghoun; Eric Wattel; Franck Mortreux
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

Review 5.  Protein kinase C isoenzymes: divergence in signal transduction?

Authors:  H Hug; T F Sarre
Journal:  Biochem J       Date:  1993-04-15       Impact factor: 3.857

6.  Determination of the c-MYC DNA-binding site.

Authors:  T D Halazonetis; A N Kandil
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

7.  Therapeutic Targeting of Myc.

Authors:  Edward V Prochownik; Peter K Vogt
Journal:  Genes Cancer       Date:  2010-06

8.  The ornithine decarboxylase gene is a transcriptional target of c-Myc.

Authors:  C Bello-Fernandez; G Packham; J L Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

9.  Differential patterns of DNA binding by myc and max proteins.

Authors:  E V Prochownik; M E VanAntwerp
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

10.  Interleukin-6- and leukemia inhibitory factor-induced terminal differentiation of myeloid leukemia cells is blocked at an intermediate stage by constitutive c-myc.

Authors:  B Hoffman-Liebermann; D A Liebermann
Journal:  Mol Cell Biol       Date:  1991-05       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.